---
schema_version: "secwatch.filing_event.v1"
accession: "0001062993-26-003545"
form_type: "8-K"
ticker: "CNXU"
cik: "0002066836"
company_name: "Conexeu Sciences Inc."
filed_at: "2026-07-07T21:12:57+00:00"
generated_at: "2026-07-07T21:14:11.578241+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Conexeu Sciences completes 12-month preclinical P.R.O.O.F study for CXU platform

## Summary
- 12-month preclinical study met objectives for tissue restoration in cheek and 200cc-equivalent models.
- CXU platform met injectability and volumizing performance benchmarks for aesthetic injectables.
- GLP-1 weight-loss drug market projected to reach ~$190B by 2035, driving tissue-restoration gap to $2B by 2030.
- Company plans predicate-based 510(k) submission for wound care in Q1 2027, targeting 90-day FDA review.
- Patent estate spans over 40 jurisdictions including U.S., EU, Japan, and Australia.

## SEC filing metadata
- accession: 0001062993-26-003545
- form_type: 8-K
- ticker: CNXU
- cik: 0002066836
- company_name: Conexeu Sciences Inc.
- filed_at: 2026-07-07T21:12:57+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2066836/000106299326003545/0001062993-26-003545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2066836/000106299326003545/form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001062993-26-003545
- JSON: https://secwatch.observer/filing/0001062993-26-003545.json
- Plain text: https://secwatch.observer/filing/0001062993-26-003545.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.